Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Proteinuria in diabetic nephropathy: treatment and evolution.

Campbell RC, Ruggenenti P, Remuzzi G.

Curr Diab Rep. 2003 Dec;3(6):497-504. Review.

PMID:
14611747
2.

Introduction: nature of microalbuminuria, proteinuria, and progressive renal disease.

Mogensen CE.

J Diabetes Complications. 1995 Jan-Mar;9(1):2-6. Review. No abstract available.

PMID:
7734738
3.
4.

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P; VA NEPHRON-D Investigators.

Clin J Am Soc Nephrol. 2009 Feb;4(2):361-8. doi: 10.2215/CJN.03350708. Epub 2008 Dec 31.

5.

The RAAS in the pathogenesis and treatment of diabetic nephropathy.

Ruggenenti P, Cravedi P, Remuzzi G.

Nat Rev Nephrol. 2010 Jun;6(6):319-30. doi: 10.1038/nrneph.2010.58. Epub 2010 May 4. Review.

PMID:
20440277
6.

Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.

Yokoyama H, Tomonaga O, Hirayama M, Ishii A, Takeda M, Babazono T, Ujihara U, Takahashi C, Omori Y.

Diabetologia. 1997 Apr;40(4):405-11.

PMID:
9112017
8.

Albuminuria: a target for treatment of type 2 diabetic nephropathy.

de Zeeuw D.

Semin Nephrol. 2007 Mar;27(2):172-81. Review.

PMID:
17418686
10.

[Nephroprotection in young type 1 diabetic patients treated with converting enzyme inhibitor].

Benamar L, Laboudi A, Rhou H, Laouad I, Fahi Z, Bentata Y, Amar Y, Ezzaïtouni F, Ouzeddoun N, Bayahia R, Balafrej L, Touzani A, Benhamou B, Balafrej A, Guedira A.

Presse Med. 2003 Apr 12;32(14):638-43. French.

PMID:
12714902
12.

Diabetic nephropathy: pathogenetic basis for treatment.

Reasner CA 2nd, DeFronzo R.

Contemp Intern Med. 1994 Oct;6(10):30-2, 35-40.

PMID:
10150289
13.

[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

Presse Med. 2002 Nov 9;31(36):1714-20. Review. French.

PMID:
12467154
14.

Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.

Suzuki H, Kanno Y, Nakamoto H, Okada H, Sugahara S.

Clin Exp Hypertens. 2005 Feb-Apr;27(2-3):129-38.

PMID:
15835375
15.

Proteinuria and progression of renal disease: therapeutic implications.

Gansevoort RT, Navis GJ, Wapstra FH, de Jong PE, de Zeeuw D.

Curr Opin Nephrol Hypertens. 1997 Mar;6(2):133-40. Review.

PMID:
9146974
16.

Prevention of diabetic nephropathy.

Materson BJ, Preston RA.

Hosp Pract (1995). 1997 Feb 15;32(2):129-34, 139-40. Review.

PMID:
9040425
17.

Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases.

Mimran A, Ribstein J.

Am J Hypertens. 1994 Sep;7(9 Pt 2):73S-81S. Review.

PMID:
7818839
18.

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.

Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G.

Am J Kidney Dis. 2000 Jun;35(6):1155-65.

PMID:
10845831
19.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
20.

Chemoprophylaxis of diabetic nephropathy in the elderly.

Jungmann E.

Drugs Aging. 1996 Dec;9(6):449-57. Review.

PMID:
8972244

Supplemental Content

Support Center